CANCER Research Technology (CRT) has purchased 2,000 Maybridge Fragments as the foundation of its new fragment screening library.

Wholly owned by the internationally renowned charity, Cancer Research UK, CRT is a specialist oncology-focused development and commercialisation company. Selected for its high quality, the Maybridge Fragment Collection will be used in CRT's established discovery laboratories in London and Cambridge, for fragment-based screening, a key technology to accelerate the identification of drug leads against novel cancer targets.

Maybridge, near Tintagel, is part of Thermo Fisher Scientific, and is well known for providing highly innovative drug-like molecules and screening compounds for drug discovery and development.

"We are very proud to have been selected by such an eminent cancer technology transfer company due to the quality, diversity and flexibility of our Fragment Collection," said Dr Mick Durrant, director of business development for Maybridge products at Thermo Fisher Scientific. "We pride ourselves on our choice of off-the-shelf collections and the ability to pick from our carefully selected fragment lists. This enables our customers to create their own bespoke libraries, giving them both convenience and complete control over their fragment screening programmes to ultimately accelerate lead generation."

The Maybridge Fragment collection is a convenient source of pre-selected, high quality building blocks which is a distillation of Maybridge's combined expertise in heterocyclic compound design. Over 30,000 compounds have been assembled to form a pool from which researchers can build their own customised fragment libraries.